Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTMC0658 in chronic rhinosinusitis without nasal polyps
NCT07174115Phase 2Recruiting
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HTMC0658 in chronic rhinosinusitis (CRS), sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.. Started Aug 2025; status: recruiting.
02
Drugs
HTMC0658
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT07174115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174115.